Which is the optimal adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma?: A protocol for a network meta-analysis of randomized controlled trials

BACKGROUND: Although adjuvant chemotherapy has been shown to reduce relapse and prolong survival after surgery, it is still unclear which adjuvant chemotherapy regimen will be favorable over the all adjuvant treatments evaluated for patients with resected pancreatic ductal adenocarcinoma. METHODS: P...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Qiancheng, Wang, Xin, Chen, Ye, Li, Xiaofen, Cao, Peng, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571414/
https://www.ncbi.nlm.nih.gov/pubmed/31124963
http://dx.doi.org/10.1097/MD.0000000000015761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571414/
https://www.ncbi.nlm.nih.gov/pubmed/31124963
http://dx.doi.org/10.1097/MD.0000000000015761

Ejemplares similares